Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
Jetstar to Charge for Overhead Cabin Bags From February 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
Apple Restores Telegram to App Store After Content Policy Violation 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
HAUPPAUGE, N.Y., March 22, 2018 -- United-Guardian, Inc., (NASDAQ:UG) reported today that net income for FY-2017 increased by 49% over the previous year, rising from $2,581,142 ($0.56 per share) in 2016 to $3,844,290 ($0.84 per share) in 2017. Sales for the year were up from $11,144,462 in 2016 to $13,434,460 in 2017, an increase of 21%.
Ken Globus, President of United-Guardian, stated, “We had a significant increase in both sales and earnings in 2017, which was the result of both a 40% increase in sales of our cosmetic ingredients and an 18% increase in sales of our most important pharmaceutical product, Renacidin® Irrigation. The increase in sales of our cosmetic ingredients was due primarily to renewed sales of one of our Lubrajel® products in China, and the increase in Renacidin sales was mainly the result of this being the first full fiscal year of sales of our new single-dose form of that product. We have retained a web consultant to assist us in expanding our marketing efforts for Renacidin via our new Renacidin web site (www.renacidin.com). With some of our new “natural” cosmetic ingredients being actively promoted globally right now, as well as additional “natural” products in varying stages of development, we are optimistic that we will be able to further expand sales of both our cosmetic ingredients and Renacidin as the year progresses.”
United-Guardian is a manufacturer of cosmetic ingredients, personal and health care products, pharmaceuticals, and specialty industrial products.
Contact: Robert S. Rubinger
(631) 273-0900
NOTE: This press release contains both historical and "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company’s expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the “safe harbor” provisions of that Act. Such statements are subject to a variety of factors that could cause the company’s actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company’s business please refer to the company's reports and filings with the Securities and Exchange Commission.
FINANCIAL RESULTS FOR THE YEARS ENDED
DECEMBER 31, 2017 AND DECEMBER 31, 2016
STATEMENTS OF INCOME
| Years ended December 31, | ||||||
| 2017 | 2016 | |||||
| Sales: | ||||||
| Gross Sales | $ | 13,434,460 | $ | 11,144,462 | ||
| Sales allowances and returns | (466,255 | ) | (367,595 | ) | ||
| Net sales | 12,968,205 | 10,776,867 | ||||
| Costs and expenses: | ||||||
| Cost of sales | 5,301,352 | 4,882,644 | ||||
| Operating expenses | 1,785,160 | 1,852,833 | ||||
| Research and development | 646,079 | 651,828 | ||||
| Total costs and expenses | 7,732,591 | 7,387,305 | ||||
| Income from operations | 5,235,614 | 3,389,562 | ||||
| Investment income | 315,165 | 306,505 | ||||
| Income before provision for income taxes | 5,550,779 | 3,696,067 | ||||
| Provision for income taxes | 1,706,489 | 1,114,925 | ||||
| Net income | $ | 3,844,290 | $ | 2,581,142 | ||
| Earnings per common share (basic and diluted) | $ | 0.84 | $ | 0.56 | ||
| Weighted average shares (basic and diluted) | 4,594,319 | 4,594,319 | ||||
BALANCE SHEET DATA
(condensed)
| December 31, | ||||||
| 2017 | 2016 | |||||
| Current assets | $ | 11,850,522 | $ | 13,714,172 | ||
| Net property, plant, and equipment | 942,887 | 1,090,591 | ||||
| Deferred income taxes (net) | --- | 2,382 | ||||
| Other assets (net) | 59,471 | 59,295 | ||||
| Total assets | 12,852,880 | 14,866,440 | ||||
| Current liabilities | 1,422,383 | 1,045,951 | ||||
| Deferred income taxes (net) | 33,855 | --- | ||||
| Total Liabilities | 1,456,238 | 1,045,951 | ||||
| Stockholders’ equity | 11,396,642 | 13,820,489 | ||||
| Total liabilities and stockholders’ equity | $ | 12,852,880 | $ | 14,866,440 | ||
